126 related articles for article (PubMed ID: 23241284)
1. Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement.
Moreau C; Bajolle F; Siguret V; Loriot MA; Bonnet D
J Thromb Haemost; 2013 Mar; 11(3):555-72. PubMed ID: 23241284
[No Abstract] [Full Text] [Related]
2. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
[No Abstract] [Full Text] [Related]
3. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
6. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
Biss TT; Kamali F
Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
[No Abstract] [Full Text] [Related]
7. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
8. Genetics of warfarin response.
Mannucci PM; Spreafico M; Peyvandi F
N Engl J Med; 2008 Jun; 358(25):2743; author reply 2743-4. PubMed ID: 18572453
[No Abstract] [Full Text] [Related]
9. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
11. Optimal INR level for warfarin therapy after mechanical mitral valve replacement.
Kamthornthanakarn I; Krittayaphong R
BMC Cardiovasc Disord; 2019 Apr; 19(1):97. PubMed ID: 31023235
[TBL] [Abstract][Full Text] [Related]
12. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
[TBL] [Abstract][Full Text] [Related]
13. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
[TBL] [Abstract][Full Text] [Related]
14. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events.
Santos PC; Soares RA; Strunz CM; Grinberg M; Ferreira JF; Cesar LA; Scanavacca M; Krieger JE; Pereira AC
J Manag Care Spec Pharm; 2014 Apr; 20(4):376-81. PubMed ID: 24684642
[TBL] [Abstract][Full Text] [Related]
16. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.
Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
Blood; 2008 Apr; 111(7):3903-4. PubMed ID: 18362220
[No Abstract] [Full Text] [Related]
17. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
18. Multiple gene polymorphisms and warfarin sensitivity.
Shikata E; Ieiri I; Ishiguro S; Takane H; Ohgi S; Otsubo K
Eur J Clin Pharmacol; 2006 Oct; 62(10):881-3. PubMed ID: 16821005
[No Abstract] [Full Text] [Related]
19. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
20. Genetic testing for warfarin dosing? Not yet ready for prime time.
Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
